Literature DB >> 15477412

Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey.

Sarah D de Ferranti1, Kimberlee Gauvreau, David S Ludwig, Ellis J Neufeld, Jane W Newburger, Nader Rifai.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) is defined by the Third Report of the Adult Treatment Panel (ATP III) using criteria easily applied by clinicians and researchers. There is no standard pediatric definition. METHODS AND
RESULTS: We defined pediatric MetS using criteria analogous to ATP III as > or =3 of the following: (1) fasting triglycerides > or =1.1 mmol/L (100 mg/dL); (2) HDL <1.3 mmol/L (50 mg/dL), except in boys aged 15 to 19 years, in whom the cutpoint was <1.2 mmol/L (45 mg/dL); (3) fasting glucose > or =6.1 mmol/L (110 mg/dL); (4) waist circumference >75th percentile for age and gender; and (5) systolic blood pressure >90th percentile for gender, age, and height. MetS prevalence in US adolescents was estimated with the Third National Health and Nutritional Survey 1988 to 1994. Among 1960 children aged > or =12 years who fasted > or =8 hours, two thirds had at least 1 metabolic abnormality, and nearly 1 in 10 had MetS. The racial/ethnic distribution was similar to adults: Mexican-Americans, followed by non-Hispanic whites, had a greater prevalence of MetS compared with non-Hispanic blacks (12.9%, [95% CI 10.4% to 15.4%]; 10.9%, [95% CI 8.4% to 13.4%]; and 2.5%, [95% CI 1.3% to 3.7%], respectively). Nearly one third (31.2% [95% CI 28.3% to 34.1%]) of overweight/obese adolescents had MetS.
CONCLUSIONS: Our definition of pediatric MetS, designed to be closely analogous to ATP III, found MetS is common in adolescents and has a similar racial/ethnic distribution to adults in this representative national sample. Because childhood MetS likely tracks into adulthood, early identification may help target interventions to improve future cardiovascular health.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477412     DOI: 10.1161/01.CIR.0000145117.40114.C7

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  277 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

2.  General versus central adiposity and relationship to pediatric metabolic risk.

Authors:  Jason A Mendoza; Theresa A Nicklas; Yan Liu; Janice Stuff; Tom Baranowski
Journal:  Metab Syndr Relat Disord       Date:  2011-12-13       Impact factor: 1.894

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  Prevalence of pediatrics metabolic syndrome (PMS) amongst children in the age group of 6-18 years belonging to high income group residing in national capital territory (NCT) of Delhi.

Authors:  Umesh Kapil; Supreet Kaur
Journal:  Indian J Pediatr       Date:  2010-09-08       Impact factor: 1.967

5.  The metabolic syndrome in healthy, multiethnic adolescents in Toronto, Ontario: the use of fasting blood glucose as a simple indicator.

Authors:  Vladimir Vuksan; Valentina Peeva; Alexander Rogovik; Uljana Beljan-Zdravkovic; Mark Stavro; Alexandra Jenkins; Andre G Dias; Sudi Devanesen; John Sievenpiper; Amir Hanna
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

6.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

Review 7.  Cardiovascular and Metabolic Complications - Diagnosis and Management in Obese Children.

Authors:  Naval K Vikram
Journal:  Indian J Pediatr       Date:  2017-12-08       Impact factor: 1.967

8.  Early testing of insulin resistance: a tale of two lipid ratios in a group of 5th graders screened by the Coronary Artery Risk Detection in Appalachian Communities Project (CARDIAC Project).

Authors:  Charles Ituka Mosimah; Christa Lilly; Awung-Njia Forbin; Pamela J Murray; Lee Pyles; Elloise Elliot; William Neal
Journal:  World J Pediatr       Date:  2019-05-04       Impact factor: 2.764

Review 9.  Role of autophagy in metabolic syndrome-associated heart disease.

Authors:  Sidney Y Ren; Xihui Xu
Journal:  Biochim Biophys Acta       Date:  2014-05-05

10.  Metabolic syndrome in adolescents with spinal cord dysfunction.

Authors:  Mindy Dopler Nelson; Lana M Widman; Richard Ted Abresch; Kimber Stanhope; Peter J Havel; Dennis M Styne; Craig M McDonald
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.